231 related articles for article (PubMed ID: 33520633)
21. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
[TBL] [Abstract][Full Text] [Related]
22. Metabologenomics approach to the discovery of novel compounds from
Melinda YN; Widada J; Wahyuningsih TD; Febriansah R; Damayanti E; Mustofa M
Heliyon; 2021 Nov; 7(11):e08308. PubMed ID: 34746476
[TBL] [Abstract][Full Text] [Related]
23. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
J Biosci; 2020; 45(1):. PubMed ID: 33184246
[TBL] [Abstract][Full Text] [Related]
24. Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System.
Costa LB; Perez LG; Palmeira VA; Macedo E Cordeiro T; Ribeiro VT; Lanza K; Simões E Silva AC
Front Cell Dev Biol; 2020; 8():559841. PubMed ID: 33042994
[TBL] [Abstract][Full Text] [Related]
25. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
26. Population-Specific
Hashizume M; Gonzalez G; Ono C; Takashima A; Iwasaki M
Viruses; 2021 Jan; 13(1):. PubMed ID: 33418950
[TBL] [Abstract][Full Text] [Related]
27. In silico molecular docking of SARS-CoV-2 surface proteins with microbial non-ribosomal peptides: identification of potential drugs.
Bansal P; Kumar R; Singh J; Dhanda S
J Proteins Proteom; 2021; 12(3):177-184. PubMed ID: 34456530
[TBL] [Abstract][Full Text] [Related]
28. Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An
Akinlalu AO; Chamundi A; Yakumbur DT; Afolayan FID; Duru IA; Arowosegbe MA; Enejoh OA
Sci Afr; 2021 Sep; 13():e00845. PubMed ID: 34308004
[TBL] [Abstract][Full Text] [Related]
29. [Homologous modeling and binding ability analysis of Spike protein after point mutation of severe acute respiratory syndrome coronavirus 2 to receptor proteins and potential antiviral drugs].
Cao Z; Wang LT; Liu ZM
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 53(1):150-158. PubMed ID: 33550350
[TBL] [Abstract][Full Text] [Related]
30. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
31. An
Bahadur Gurung A; Ajmal Ali M; Elshikh MS; Aref I; Amina M; Lee J
Saudi J Biol Sci; 2022 Jun; 29(6):103297. PubMed ID: 35475118
[TBL] [Abstract][Full Text] [Related]
32. Identification of Cyanobacteria-Based Natural Inhibitors Against SARS-CoV-2 Druggable Target ACE2 Using Molecular Docking Study, ADME and Toxicity Analysis.
Sahu N; Mishra S; Kesheri M; Kanchan S; Sinha RP
Indian J Clin Biochem; 2023 Jul; 38(3):361-373. PubMed ID: 35812791
[TBL] [Abstract][Full Text] [Related]
33. Molecular optimization, docking, and dynamic simulation profiling of selective aromatic phytochemical ligands in blocking the SARS-CoV-2 S protein attachment to ACE2 receptor: an
Dey D; Paul PK; Al Azad S; Al Mazid MF; Khan AM; Sharif MA; Rahman MH
J Adv Vet Anim Res; 2021 Mar; 8(1):24-35. PubMed ID: 33860009
[TBL] [Abstract][Full Text] [Related]
34. Molecular docking, DFT analysis, and dynamics simulation of natural bioactive compounds targeting ACE2 and TMPRSS2 dual binding sites of spike protein of SARS CoV-2.
Yadav R; Hasan S; Mahato S; Celik I; Mary YS; Kumar A; Dhamija P; Sharma A; Choudhary N; Chaudhary PK; Kushwah AS; Chaudhary JK
J Mol Liq; 2021 Nov; 342():116942. PubMed ID: 34305216
[TBL] [Abstract][Full Text] [Related]
35.
Pagliarin LG; de Oliveira LM; Dos Anjos VNF; de Souza CBT; Peiter GC; Façanha Wendel C; Dillmann Groto A; Freire de Melo F; Teixeira KN
World J Biol Chem; 2023 Jul; 14(4):72-83. PubMed ID: 37547340
[TBL] [Abstract][Full Text] [Related]
36. In silico identification of compounds from
Duru CE; Duru IA; Adegboyega AE
Bull Natl Res Cent; 2021; 45(1):57. PubMed ID: 33727782
[TBL] [Abstract][Full Text] [Related]
37. Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex.
Haritha M; Suresh CH
J Biomol Struct Dyn; 2023; 41(15):7354-7364. PubMed ID: 36099187
[TBL] [Abstract][Full Text] [Related]
38. Molecular docking of ethanol extracts of katuk leaf (
Makati AC; Ananda AN; Putri JA; Amellia SF; Setiawan B
S Afr J Bot; 2022 Sep; 149():1-5. PubMed ID: 35668920
[TBL] [Abstract][Full Text] [Related]
39. Exploring the viability of Zeatin as a prospective therapeutic candidate for investigating the complex interplay between severe acute respiratory syndrome coronavirus (SARS-CoV) and Alzheimer's disease.
Sriranjini AS; Thapliyal A; Pant K
In Silico Pharmacol; 2024; 12(1):21. PubMed ID: 38559708
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion.
Tian X; Shen L; Gao P; Huang L; Liu G; Zhou L; Peng L
Front Microbiol; 2022; 13():740382. PubMed ID: 35295301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
